Marijuana doesn’t fit neatly into one drug category. It can act as a depressant, a stimulant, and a hallucinogen depending on the strain, the dose, and the individual person. This makes it unusual among commonly used substances, most of which fall cleanly into a single pharmacological class. Beyond drug effects, marijuana also has a specific legal classification under federal law and a defined place in plant taxonomy.
Depressant, Stimulant, and Hallucinogen at Once
Most drugs are categorized by their dominant effect on the nervous system. Depressants slow brain activity and produce relaxation. Stimulants speed it up and increase alertness. Hallucinogens alter perception and the sense of reality. Marijuana produces all three types of effects, which is why pharmacologists often place it in its own category or list it under multiple classes simultaneously.
The depressant effects are what most users recognize first. THC, the primary mind-altering compound in the plant, can make people feel relaxed, sleepy, and physically calm. It slows reaction time and impairs coordination, much like alcohol or sedatives. One terpene found in many cannabis strains, called myrcene, contributes to the heavy sedation sometimes described as “couch lock” when present at higher concentrations.
At lower doses or with certain strains, marijuana can also act as a stimulant, increasing heart rate, elevating mood, and producing a sense of energy or euphoria. Some compounds in the plant boost levels of serotonin and dopamine, the same brain chemicals targeted by classic stimulant drugs.
The hallucinogenic side shows up as altered time perception, changes in sensory experience, and shifts in how reality feels. THC causes changes in mood, thoughts, and perceptions of reality. These effects are typically milder than those of classic hallucinogens like psilocybin or LSD, but they place cannabis partly in that category as well.
How THC and CBD Create Different Effects
The cannabis plant produces over a hundred chemical compounds called cannabinoids, but two dominate the conversation. THC is the principal psychoactive compound, responsible for the “high.” CBD is its non-psychoactive sibling. Despite having very similar chemical structures, they work through different mechanisms in the brain and produce dramatically different effects.
Your body has its own endocannabinoid system, a network of receptors (called CB1 and CB2) that naturally regulate mood, pain, appetite, and memory. THC binds directly to CB1 receptors concentrated in the brain, which is why it alters consciousness. CBD does not bind to these receptors in the same way and does not produce intoxication. This distinction is central to how cannabis products are categorized for both medical and legal purposes.
One sesquiterpene compound commonly found in cannabis, beta-caryophyllene (the source of its peppery aroma), actually binds to CB2 receptors without producing any psychoactive effects. It contributes to the plant’s anti-inflammatory properties and illustrates why cannabis chemistry is more complex than a simple “drug category” label suggests.
Federal Legal Classification: Schedule I
Under the Controlled Substances Act, marijuana is currently classified as a Schedule I drug. This is the most restrictive federal category, reserved for substances defined as having no currently accepted medical use, a high potential for abuse, and no accepted safety profile for use under medical supervision. Heroin and LSD share this classification.
That classification is actively being reconsidered. In 2023, the Department of Health and Human Services recommended moving marijuana to Schedule III, a category for drugs with accepted medical uses and a lower potential for abuse. The FDA and the National Institute on Drug Abuse both supported the change. In May 2024, the Department of Justice issued a proposed rule to make the rescheduling official, receiving nearly 43,000 public comments. As of the most recent federal action, the rulemaking process is moving forward but awaiting an administrative law hearing.
Schedule III would place marijuana alongside drugs like certain anabolic steroids and some combination medications containing lower amounts of narcotics. The practical impact would be significant for research access and potentially for how cannabis businesses are taxed, though it would not make recreational marijuana legal under federal law.
State-Level Medical and Recreational Categories
While federal law maintains a single classification, states have created their own two-tier system. As of February 2024, 38 states, the District of Columbia, and three territories operate comprehensive medical cannabis programs that allow patients with qualifying conditions to use cannabis products containing meaningful levels of THC. Another nine states restrict medical use to CBD or low-THC products only. In total, 47 states permit some form of medical cannabis.
Recreational (or “adult use”) marijuana is a separate legal category. Twenty-four states, the District of Columbia, and two territories allow adults to purchase and use cannabis without a medical reason. The distinction between medical and recreational programs typically comes down to qualifying conditions, purchase limits, product potency, and taxation rates rather than any difference in the plant itself.
FDA-Approved Cannabinoid Medications
The FDA has carved out a small but important pharmaceutical category for cannabis-derived and cannabis-related drugs. Epidiolex, which contains purified CBD, is approved for treating seizures associated with three specific conditions: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex, in patients one year of age and older.
Two synthetic THC medications, Marinol and Syndros, are approved for treating severe nausea from chemotherapy and appetite loss associated with AIDS. A third synthetic, Cesamet, has a chemical structure similar to THC and treats the same conditions. These medications are all scheduled differently from whole-plant marijuana, reflecting how federal drug categories can separate a plant from its individual chemical components.
Botanical Classification
From a purely scientific standpoint, marijuana belongs to the plant family Cannabaceae, which it shares with hops (the plant used to flavor beer). The genus is Cannabis, and the species is Cannabis sativa. Within that species, botanists recognize two primary subspecies based on DNA analysis: Cannabis sativa subsp. sativa and Cannabis sativa subsp. indica. These correspond loosely to what consumers know as “sativa” and “indica” strains, though modern breeding has blurred the genetic lines considerably.
The Cannabaceae family has expanded in recent years through taxonomic reclassification and now includes ten genera total, but Cannabis and Humulus (hops) remain its most well-known members.